Teva Pharmaceutical Industries to present MS treatment research data

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced that new research data furthering the clinical understanding of its diverse multiple sclerosis (MS) treatment franchise will be presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Düsseldorf, Germany, September 9-12, 2009. Featured presentations and abstracts will include new data on COPAXONE®, the global leading treatment for relapsing-remitting multiple sclerosis (RRMS), as well as on the company's compounds in advanced development.

"For nearly two decades Teva has supported the MS community and our ongoing commitment to research and development will continue to provide effective MS treatments while maintaining safety as well as contribute to a greater understanding of the disease,” said Moshe Manor, Teva’s Group Vice President, Global Branded Products. “Our dedication has not only brought forth the world’s leading MS treatment, COPAXONE®, but we are looking forward to continually support the MS community through our evolving pipeline, led by oral laquinimod.”

Teva will present data on the effect of COPAXONE® on the Multiple Sclerosis Severity Score (MSSS) from the longest ongoing prospective study of an immunomodulatory therapy in RRMS. In addition, Teva and Active Biotech (NASDAQ OMX NORDIC: ACTI) will present data on laquinimod, its investigational oral, once-daily, immunomodulating compound being developed for the treatment of RRMS. New data on ATL/TV1102, a second generation antisense inhibitor of CD49d, a subunit of VLA-4, for the treatment of RRMS patients, will be presented as well.

Platform Presentations/Poster Sessions*

COPAXONE® Clinical Studies

  • Characterization of signal transduction pathways involved in glatiramer acetate (copolymer-1, Copaxone)-induced type II monocyte differentiation (Young Researcher’s Session I, September 9)
  • CD161/CCR6 (IL-17 associated) expression in relapsing multiple sclerosis: effect of glatiramer acetate on immune regulation (Poster #276, September 10)
  • Improvement on the Multiple Sclerosis Severity Score after 10 and 15 years of glatiramer acetate treatment (Poster #415, September 10)
  • Glatiramer acetate induced Foxp3 regulatory T-cells contribute to its therapeutic effect in experimental autoimmune encephalomyelitis (Poster #638, September 11)

* Does not include all Teva sponsored studies featured at ECTRIMS


  • Anti-inflammatory pathways activated by laquinimod in CD4+, CD8+, CD14+, CD19+ and NK peripheral blood cells subtypes of relapsing-remitting multiple sclerosis patients (Poster #264, September 10)
  • Reduced inflammation, demyelination and axonal damage after therapeutic laquinimod treatment in experimental autoimmune encephalomyelitis (Poster #441, September 10)
  • Long-term open extension of oral laquinimod in patients with relapsing multiple sclerosis shows favorable safety and sustained low relapse rate and MRI activity (Poster #443, September 10)
  • The effect of laquinimod on lymphocyte VLA-4 properties under shear flow conditions (Poster #628, September 11)
  • Laquinimod induces up-regulation of neurotrophins in serum of patients with relapsing-remitting multiple sclerosis (Poster #783, September 11)
  • The effect of laquinimod on the distribution of monocyte subsets (Poster #808, September 11)


  • Prediction of optimal dosing regimen for TV-1102, a novel anti VLA-4 antisense drug (Poster #435, September 10)


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Research reveals light's impact on metabolism beyond circadian rhythms